Research programme: HIV integrase inhibitors - Pharmacor

Drug Profile

Research programme: HIV integrase inhibitors - Pharmacor

Alternative Names: HIV integrase inhibitors research programme - Pharmacor

Latest Information Update: 22 Mar 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmacor
  • Class
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 22 Mar 2006 Discontinued - Preclinical for HIV infections treatment in Canada (unspecified route)
  • 07 May 2003 Pharmacor has been acquired by Procyon Biopharma
  • 23 Dec 2002 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top